Testing blood and tumor markers to guide lymphoma treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at “biomarkers” (measurable signs in your tumor and possibly blood) to understand your lymphoma’s genetic make-up. The goal is to see which markers may help doctors decide on treatment and timing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to take part in the study (no refusal of participation)
- You have been diagnosed with a lymphoma type such as diffuse large B-cell lymphoma or other specified lymphomas
- You are not currently on lymphoma treatment, or you only had steroids in the past 14 days (up to a total of 500 mg)
- Your care team expects you will need whole-body (systemic) treatment within 30 days of screening
- You have not had lymphoma treated only with surgery and/or local radiation for a limited area
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at blood samples to measure substances that may reflect cancer (tumor markers). It may help doctors understand cancer better and improve future monitoring, as long as you can safely and regularly take part.
This study checks whether measuring a blood test called “circulating tumor DNA” (ctDNA) helps monitor childhood lymphoma during treatment. It’s meant to see if ctDNA tracking can provide useful information alongside standard exams.
This study measures “circulating tumor markers,” meaning substances from cancer that can show up in blood, to better understand how cancer is doing after treatment. You may join if you recently received cancer care at a participating center and meet basic study and follow-up requirements.
This study looks at certain markers on your blood cancer cells to understand them better. By joining, you help doctors learn more about your disease, which may guide future care.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
Hear when a new Lymphomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.